We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
Date | Subject | Author | Discuss |
---|---|---|---|
07/6/2019 15:13 | I'm hoping we hear some news in the next week or two, probably, as someone mentioned earlier on a licensing deal in the US. The Conference RNS is pretty specific on that when read in hindsight "the Company's management team will be participating in 1-2-1 meetings". I'm sure such meetings would go better if the other party had an update to the existing trails. I'm sure I would be asking before signing to hand over the money.Just topped up at 255 which kind of negates what I was saying in my last sentence, Lol! | esmerelda | |
07/6/2019 14:12 | maybe we should train those lovely stem cells to look for gold, sure they can do it....:-) | martinfrench | |
07/6/2019 14:10 | I remember someone predicting the shareprice would eventually retrace to 240 before the next lift. | masingi | |
07/6/2019 12:53 | Agreed. My purchase this morning was listed as a sale and, looking at the sell trades there appears to be numerous cases of double counting. | dickbush | |
07/6/2019 12:49 | and my buy shown as a sell....the list of "sells" over on lse ridiculous and not true, something going on here.... | martinfrench | |
07/6/2019 12:44 | I certainly didn't see today's initial weakness leading to further weakness when the market is in such a good mood. May be something to do with Woodford trying to get a large trade away. One thing's for sure, our 35% shareholder isn't going to put up more cash for a rights issue any time soon! | dickbush | |
07/6/2019 12:41 | Around the 50day ema now. Would be a nice place for a bounce | volsung | |
07/6/2019 12:36 | Perhaps the Chinese have bought a 🐷 in a poke? But I’d be mightily surprised 😯 if they had! All small trades so far. | rayrac | |
07/6/2019 12:34 | added some more | martinfrench | |
07/6/2019 12:32 | Can’t see how the quantity of shares traded so far, should have the effect it’s supposedly having right now. Lot of bs in the markets. | rayrac | |
07/6/2019 12:18 | Looking at the trades today....someone trying very hard to get the share price down???? Woody is finished....do not see him recovering from this fiasco....There was an RNS on Pruple Bricks yesterday to say he had sold some stock, so I guess we will be advised if he sells off any here...I would be surprised if he does.. it must surely be one of his best stocks, and having announced he is looking at FTSE 100 I cannot see any stock there that could go up as much as RENE could on a good RNS or 2...IMHO! GLA! | daffodil4 | |
07/6/2019 11:59 | 1 May 2019: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that the Company’s management team will be participating in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday 4 June 2019 in New York City. So, RENE isn't presenting at the conference. It's anyone's guess what the 1-on-1 meetings are about but mine would be that they are looking for another deal like the one they did with the Chinese. | dickbush | |
07/6/2019 11:06 | Biogen Inc. Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million Nightstar acquisition further bolsters Biogen’s pipeline with the addition of two mid- to late-stage clinical assets as well as preclinical programs CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced that it has completed its acquisition of Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology. The total transaction value was approximately $800 million, after taking into account expected transaction expenses and cash at closing. NST’s common stock will no longer be listed for trading on the Nasdaq Global Select Market. | cottoner | |
07/6/2019 09:44 | Anybody have access to this article in the FT? "Woodford/UK biotech: calamitous catalyst" | xow98 | |
07/6/2019 09:44 | Agreed.... It is Woodford in Trouble not RENE.. As there has not been a RNS to say anything negative has been identified in the trial at this point I think we can trust all is going well.... GLA! | daffodil4 | |
06/6/2019 10:29 | Looks like the Woodford saga has been absorbed.. Possibly he will sell 15% from the suspended fund.. it all depeneds on his take on what is illiquid.. I think at the current share price and in our window of potential significant news it would be easy to sell, as any fund wanting a decent position here has a golden opportunity..either way a good RNS and the Woodford issue is history... GLA! | daffodil4 | |
05/6/2019 13:25 | Around the 20 day ema. Should bounce nicely | volsung | |
05/6/2019 09:32 | I agree blondeamon..... | daffodil4 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions